Nektar Therapeutics Balance Sheet - Annual (NASDAQ:NKTR)

Add to My Stocks
$58.44 $1.75 (3.09%) NKTR stock closing price Sep 20, 2018 (Closing)

The financial analysis of a company like Nektar Therapeutics involves checking the three financial statements of the company in detail, of which the balance sheet is one. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Nektar Therapeutics stock analysis. Good annual results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Apart from analyzing Nektar Therapeutics revenue Nektar Therapeutics operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Nektar Therapeutics balance sheet for 2017 shows cash on hand of $4.76M. The company has a debt to equity ratio of 0.13.

View latest 10 year balance sheet data to check Nektar Therapeutics financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Cash4.76M59.64M55.57M37.36M39.06M25.43M15.31M17.75M49.59M155.58M
Marketable Securities291.37M329.46M253.37M225.45M197.95M251.75M225.85M298.17M346.61M223.41M
Receivables5.01M15.67M19.94M3.6M2.22M5.8M4.93M25.1M4.8M11.16M
Inventory10.72M11.1M11.34M12.95M13.45M18.26M12.65M7.26M6.47M9.31M
Raw Materials1.79M2.05M3.23M2.2M3.94M7.48M9.75M6.1M5.93M6.96M
Work In Progress4.84M7.31M6.08M5.18M6.14M6.66M1.21M--1.74M
Finished Goods4.08M1.74M2.02M5.56M3.35M4.11M1.68M1.16M--
Notes Receivable----------
Other Current Assets14.94M10.36M9.81M8.81M5.17M13.36M17.94M5.67M6.18M6.74M
Total Current Assets
326.82M426.25M350.05M288.2M257.88M314.63M276.7M353.97M413.66M406.22M
Property Plant & Equipment162.55M176.84M174.04M164.17M151.12M144.88M140.81M143.76M132.66M117.08M
Accumulated Depreciation115.09M111.24M102.71M93.8M84.14M72.66M62.23M53.99M54.4M43.5M
Net Property Plant & Equipment
47.46M65.6M71.33M70.36M66.97M72.21M78.57M89.77M78.26M73.57M
Investment & Advances57.08M-----173.76M---
Other Non-Current Assets----------
Deferred Charges----------
Intangibles76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M
Deposits & Other Assets--4.17M6.55M33.17M34.44M--7.08M4.23M
Total Assets
508.86M568.87M502.06M441.62M434.52M497.79M606.55M521.22M575.51M560.53M
Notes Payable----------
Accounts Payable4.78M2.81M2.36M2.7M9.11M2.86M3.01M7.19M3.06M13.83M
Current Portion Long-Term Debt------214.95M---
Current Portion Capital Leases-2.9M4.75M4.51M------
Accrued Expenses31.98M35.14M22.57M26.79M44.31M41.36M31.42M29.93M28.57M39.11M
Income Taxes Payable----------
Other Current Liabilities19.39M31.35M31.55M30.04M44.78M34.31M26.12M26.97M121.37M15.42M
Total Current Liabilities
56.16M72.22M61.24M64.04M98.22M78.53M275.53M64.1M153.01M68.37M
Mortgages----------
Deferred Taxes/Income19.02M51.88M62.42M76.91M82.38M98.95M111.46M128.91M81.83M61.46M
Convertible Debt-------214.95M214.95M214.95M
Long-Term Debt245.2M243.46M242.11M125M125M125M----
Non-Current Capital Leases-2.22M1.07M4.13M8.04M11.6M14.58M17.01M18.8M20.34M
Other Long-Term Liabilities100.64M110.95M128.77M135.19M210.77M136.67M7.15M5.57M4.54M5.23M
Total Liabilities
421.03M480.74M495.63M405.28M524.43M450.77M408.73M430.56M473.15M370.38M
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus2.21B2.11B1.88B1.82B1.64B1.62B1.6B1.35B1.33B1.31B
Retained Earnings-2.12B-2.02B-1.87B-1.79B-1.73B-1.57B-1.4B-1.26B-1.23B-1.12B
Treasury Stock----------
Other Liabilities-2.11M-2.36M-2.17M-1.56M-1.18M-0.35M-1.1M-1.02M1.43M
Shareholders Equity87.82M88.12M6.42M36.33M-89.9M47.01M197.81M90.66M102.36M190.15M
Total Liabilities & Shareholders Equity508.86M568.87M502.06M441.62M434.52M497.79M606.55M521.22M575.51M560.53M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The latest Nektar Therapeutics stock price, and Nektar Therapeutics historical stock prices show the stock price movement over time, and the Nektar Therapeutics PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: Anything that the Nektar Therapeutics company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Nektar Therapeutics had total assets of $508.86M.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Nektar Therapeutics is $421.03M. Shareholders' equity comes under liabilities as it is money the company owes the holders of NKTR stock.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
19.67
Debt to equity ratio
0.13
Asset turnover ratio
3.1
Receivables turnover
108.46
Price to book ratio
23.91